Inhibikase Therapeutics, Inc.

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. is a pharmaceutical company focused on innovating small molecule kinase inhibitor therapeutics to impact patient lives by treating diseases such as pulmonary arterial hypertension at their origin.

Products & Services

IkT-001 for PAH:A therapeutic product targeting pulmonary arterial hypertension.

IKT-001

Specialties

Small molecule kinase inhibitor therapeutics Pulmonary arterial hypertension treatment small molecule kinase inhibitor therapeutics pulmonary arterial hypertension

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: approximately $100.0 million FAN: 100000000	D: 2025-11-20 FD: 2025-11-20	7 investors
2	RT: Private Placement T: - FT: Private Placement	A: 110000000 MR: - FA: approximately $110 million FAN: 110000000	D: 2024-10-09 FD: 2024-10-09	11 investors
3	RT: Registered Direct Offering and Warrant Inducement T: - FT: Registered Direct Offering and Warrant Inducement	A: 4000000 MR: - FA: $4.0 Million FAN: 4000000	D: 2024-05-20 FD: 2024-05-20	1 investors
4	RT: Private Placement and Registered Direct Offering T: - FT: Private Placement and Registered Direct Offering	A: 10000000 MR: - FA: approximately $10 million FAN: 10000000	D: 2023-01-27 FD: 2023-01-27	-
5	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 10000000 MR: - FA: 10 million FAN: 10000000	D: 2023-01-25 FD: 2023-01-25	-

Public Offering Latest

2025-11-20

$100.0M

7 investors (Pro only)

Private Placement 2024-10-09

$110.0M

Registered Direct Offering and Warrant Inducement 2024-05-20

$4.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mark Iwicki

Chief Executive Officer

D

David McIntyre

Chief Financial Officer

C

Chris Cabell

President, Head of Research & Development, Chief Medical Officer

J

John Adams

Chief Scientific Officer

J

Jeffrey Kagy

Chief Human Resources Officer

C

Chad Orevillo

Executive VP, Head of Development Operations

View 11 more team members with Pro

Unlock Full Team Directory

Recent News